keyword
MENU ▼
Read by QxMD icon Read
search

Oab

keyword
https://www.readbyqxmd.com/read/29781068/pelvic-floor-muscle-training-with-or-without-tibial-nerve-stimulation-and-lifestyle-changes-have-comparable-effects-on-the-overactive-bladder-a-randomized-clinical-trial
#1
Lina Bykoviene, Raimondas Kubilius, Rosita Aniuliene, Egle Bartuseviciene, Arnoldas Bartusevicius
PURPOSE: To compare effects of transcutaneous posterior tibial nerve stimulation (TPTNS) and pelvic floor muscle training (PFMT) in women with overactive bladder syndrome (OAB). MATERIAL AND METHODS: We randomized 67 women ? 18 years with OAB to three parallel groups: group I (n = 22) received life-style recommendations (LSR) only; group II (n = 24) had LSR + PFMT and group III (n = 21) had LSR + PFMT + TPTNS. Urgency, evaluated by a 3-day voiding diary before treatment and six weeks later, was the main outcome measure...
May 21, 2018: Urology Journal
https://www.readbyqxmd.com/read/29780784/risk-factors-and-factors-affecting-the-severity-of-overactive-bladder-symptoms-in-korean-women-who-use-public-health-centers
#2
Jungsoo Chae, Eun-Hee Yoo, Yeonseong Jeong, Seungyeon Pyeon, Donguk Kim
Objective: To investigate the prevalence, risk factors of overactive bladder (OAB) and the factors affecting the severity of OAB symptoms. Methods: A total 822 interviews with women aged 18-80 years who visited public health centers were conducted between April 2014 and April 2015. The questionnaire was composed of 16 questions about urinary symptoms, 14 questions about self-treatment and the use of complementary and alternative medicine, and 21 questions about socio-demographic characteristics...
May 2018: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/29777865/a-prospective-non-interventional-registry-study-of-patients-initiating-a-course-of-drug-therapy-for-overactive-bladder-perspective-rationale-design-and-methodology
#3
Eric S Rovner, Kevin V Carlson, Anna S Deal, Kavita V Nair, Eva E Oakkar, Julie Park, Eric Gemmen, Rita M Kristy, Katherine L Gooch, Carol R Schermer
INTRODUCTION: Pharmacotherapy of overactive bladder (OAB) typically involves treatment with an antimuscarinic or mirabegron, a β3-adrenoceptor agonist, but real-world evidence on their use, including treatment access, persistence, and switching, is limited. Here, we describe the design of a prospective, multicenter, non-interventional registry of patients beginning a new course of OAB pharmacological therapy in routine clinical practice. METHODS: Adults with an OAB diagnosis for at least 3 months who either initiated a new course of mirabegron or antimuscarinic, or who switched therapy were enrolled into PERSPECTIVE (A Prospective, Non-intErventional Registry Study of Patients Initiating a Course of Drug Therapy for OveractIVE Bladder)...
May 16, 2018: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/29773501/what-is-new-in-neuromodulation-for-overactive-bladder
#4
REVIEW
Manuela Tutolo, Enrico Ammirati, Frank Van der Aa
We reviewed the available studies on efficacy and safety of percutaneous tibial nerve stimulation (PTNS) and sacral nerve modulation (SNM) for overactive bladder (OAB) symptoms not responsive to conservative treatments. We limited our search to randomized trials, in English, with at least 20 adult patients, and 6 mo and 12 wk of follow-up for SNM and PTNS, respectively, published between January 1998 and December 2017. Therapeutic success ranges from 61% to 90% for SNM and from 54% to 79% for PTNS. Both techniques are effective and safe, with no life-threatening adverse effects...
May 14, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29772697/structure-activity-relationships-based-on-3d-qsar-comfa-comsia-and-design-of-aryloxypropanol-amine-agonists-with-selectivity-for-the-human-%C3%AE-3-adrenergic-receptor-and-anti-obesity-and-anti-diabetic-profiles
#5
Marcos Lorca, Cesar Morales-Verdejo, David Vásquez-Velásquez, Juan Andrades-Lagos, Javier Campanini-Salinas, Jorge Soto-Delgado, Gonzalo Recabarren-Gajardo, Jaime Mella
The wide tissue distribution of the adrenergic β3 receptor makes it a potential target for the treatment of multiple pathologies such as diabetes, obesity, depression, overactive bladder (OAB), and cancer. Currently, there is only one drug on the market, mirabegron, approved for the treatment of OAB. In the present study, we have carried out an extensive structure-activity relationship analysis of a series of 41 aryloxypropanolamine compounds based on three-dimensional quantitative structure-activity relationship (3D-QSAR) techniques...
May 16, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29767479/nocturia-is-more-bothersome-than-daytime-luts-results-from-an-observational-real-life-practice-database-including-8659-european-and-american-luts-patients
#6
Karel Everaert, Peter Anderson, Robert Wood, Fredrik L Andersson, Tove Holm-Larsen
PURPOSE: Lower urinary tract symptoms (LUTS) encompass several diagnoses, including overactive bladder (OAB) and benign prostatic hyperplasia (BPH). Nocturia is a standalone symptom, but also included in OAB and BPH. Current discussion addresses whether the overlap of the diagnoses is too broad, leading to misdiagnosis. This study explored the differences in level, causes and consequences for patients with a diagnosis of daytime LUTS compared with a diagnosis of nocturia, and discussed whether people are being treated for the symptoms that truly bother them the most...
May 16, 2018: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/29767449/outcomes-of-intradetrusor-onabotulinum-toxin-a-injection-in-patients-with-parkinson-s-disease
#7
Gregory Vurture, Benoit Peyronnet, Andrew Feigin, Milton C Biagioni, Rebecca Gilbert, Nirit Rosenblum, Steven Frucht, Alessandro Di Rocco, Victor W Nitti, Benjamin M Brucker
OBJECTIVE: To assess the safety and efficacy of intradetrusor onabotulinum toxin A injections for the treatment of overactive bladder (OAB) in patients with Parkinson's disease (PD). METHODS: All PD patients who underwent intradetrusor injections of onabotulinum toxin A (BoNT-A) for storage symptoms between 2010 and 2017 were included in a retrospective study. A 100 U dose of BoNT-A (Botox®, Allergan Irvine, CA) was used for the first injection in all patients...
May 16, 2018: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/29753213/onabotulinumtoxina-detrusor-injection-improves-female-sexual-function-in-women-with-overactive-bladder-wet-syndrome
#8
Matteo Balzarro, Emanuele Rubilotta, Andrea Braga, Silvia Bassi, Tania Processali, Walter Artibani, Maurizio Serati
OBJECTIVES: The correlation between changes in sexual function and improvements in LUTD in patients treated with OnabotulinumtoxinA (onaBoNT-A) detrusor injection is unclear and limited only to women with neurogenic OAB. The aim of this study was to evaluate the impact of OnabotulinumtoxinA (onaBoNT-A) injection on sexual function in women undergoing this treatment for idiopathic wet overactive bladder (OAB). STUDY DESIGN: This is a pilot three-center observational study including women affected by idiopathic wet overactive bladder refractory to standard conservative treatments and underwent onaBoNT-A injection...
May 5, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29752971/metabolomic-analysis-of-overactive-bladder-in-male-patients-identification-of-potential-metabolite-biomarkers
#9
Hiroshi Shimura, Takahiko Mitsui, Satoru Kira, Tatsuya Ihara, Norifumi Sawada, Hiroshi Nakagomi, Tatsuya Miyamoto, Sachiko Tsuchiya, Mie Kanda, Masayuki Takeda
OBJECTIVES: To identify metabolites that are associated with an overactive bladder (OAB) using metabolomics. PATIENTS AND METHODS: A total of 58 males without apparent neurological disease completed 24-hr bladder diaries of their micturition behavior and International Prostate Symptom Score (IPSS) for the assessment of micturition behavior and lower urinary tract symptoms. Urgency was defined as an IPSS urgency score of ≥2 (OAB group), and patients with IPSS urgency scores of ≤1 belonged to the control group...
May 9, 2018: Urology
https://www.readbyqxmd.com/read/29746857/women-undergoing-third-line-overactive-bladder-treatment-demonstrate-elevated-thermal-temporal-summation
#10
W Stuart Reynolds, Casey Kowalik, Joshua Cohn, Melissa Kaufman, Alan Wein, Roger Dmochowski, Stephen Bruehl
PURPOSE: To determine if women with overactive bladder (OAB) requiring 3rd line therapy demonstrate greater central sensitization, indexed by temporal summation to heat pain stimuli, than those with OAB. MATERIALS AND METHODS: We recruited 39 adult women with OAB from the Urology clinic who were planning to undergo interventional therapy for medication refractory OAB with either onabotulinumtoxinA bladder injection or sacral neuromodulation and 55 women with OAB, either newly seen in our Urology clinic or responding to advertisements for study participation...
May 7, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29746393/female-veterans-with-diagnoses-of-both-chronic-pelvic-pain-and-overactive-bladder-how-do-they-compare-to-women-diagnosed-with-interstitial-cystitis
#11
Katherine A Volpe, Sara B Cichowski, Yuko K Komesu, Rebecca G Rogers, Allison Murata, Glen Murata
OBJECTIVE: The objective of this study was to compare women with a known diagnosis of interstitial cystitis (IC) to a population that might be at risk for the diagnosis of IC, women with diagnoses of both chronic pelvic pain (CPP) and overactive bladder (OAB). METHODS: We conducted a retrospective study of data from the Veterans Affairs Corporate Data Warehouse. The cohort included all female veterans who had established care with a primary care provider from 1997 to present...
May 10, 2018: Female Pelvic Medicine & Reconstructive Surgery
https://www.readbyqxmd.com/read/29745000/impacts-of-serum-25-oh-vitamin-d-level-on-lower-urinary-tract-symptoms-in-male-a-step-forward-to-decrease-overactive-bladder
#12
Sangjun Yoo, Sohee Oh, Hyung Suk Kim, Han Seok Choi, Juhyun Park, Sung Yong Cho, Hwancheol Son, Hyeon Jeong, Hae Won Lee, Min Chul Cho
OBJECTIVES: To evaluate the impacts of serum vitamin D level on male lower urinary tract symptoms (LUTS). MATERIALS AND METHODS: From 2014 to 2017, 434 male patients with LUTS were included. The impacts of vitamin D on LUTS were evaluated using multivariate analysis to adjust for age, body mass index, prostate specific antigen, testosterone, Hemoglobin A1c, physical activity, and prostate volume. To exclude the effect of seasons, we also analyzed the impacts during each season...
May 9, 2018: BJU International
https://www.readbyqxmd.com/read/29732215/a-ligamentous-explanation-for-overactive-bladder-symptoms-as-defined-by-international-continence-society-in-the-female
#13
REVIEW
Peter Petros
The International Continence Society (ICS) committee has defined overactive bladder (OAB) as "a syndrome characterized by symptoms of urgency, with or without urgency incontinence, usually with increased daytime frequency and nocturia (increased night time urination). The term OAB can only be used if there is no proven infection or other obvious pathology". Though the ICS gives no anatomical basis for OAB, it is suggested that the cause is from the detrusor itself. In this review, urodynamic evidence is presented that OAB in the female may be a prematurely activated but normal micturition reflex, as predicted by the Integral Theory...
2018: Central European Journal of Urology
https://www.readbyqxmd.com/read/29725872/review-of-economic-value-drivers-of-the-treatment-of-overactive-bladder
#14
REVIEW
Sonya J Snedecor
Overactive bladder (OAB) is a symptom-driven condition with economic burden estimated to be on the order of several hundred dollars or euros per patient in some North American and European countries. This work reviews recently published economic models to evaluate how health states are defined, what cost components are considered, and what utility values are used to estimate the cost effectiveness of OAB pharmacotherapies, botulinum toxin, or sacral neuromodulation. It was found that no clear standard exists for determining OAB health states, although most were defined by some measure of incontinence frequency...
May 4, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29723926/variation-in-cardiovascular-risk-related-to-individual-antimuscarinic-drugs-used-to-treat-overactive-bladder-a-cohort-study-in-the-uk
#15
Alejandro Arana, Andrea V Margulis, Lisa J McQuay, Ryan Ziemiecki, Jennifer L Bartsch, Kenneth J Rothman, Billy Franks, Milbhor D Silva, Kwame Appenteng, Cristina Varas-Lorenzo, Susana Perez-Gutthann
BACKGROUND: Blocking muscarinic receptors could have an effect upon cardiac function, especially among elderly patients with overactive bladder (OAB). STUDY OBJECTIVE: To investigate the risk of cardiovascular events in users of antimuscarinic drugs to treat OAB. DESIGN, SETTING AND PARTICIPANTS: Cohort study of new users of darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium, aged ≥18 years old in the United Kingdom's Clinical Practice Research Datalink (CPRD), 2004-2012...
May 3, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29709423/basic-and-clinical-aspects-of-antimuscarinic-agents-used-to-treat-overactive-bladder
#16
REVIEW
Shizuo Yamada, Yoshihiko Ito, Saori Nishijima, Katsumi Kadekawa, Kimio Sugaya
Antimuscarinic agents are now widely used as the pharmacological therapy for overactive bladder (OAB) because neuronal (parasympathetic nerve) and non-neuronal acetylcholine play a significant role for the bladder function. In this review, we will highlight basic and clinical aspects of eight antimuscarinic agents (oxybutynin, propiverine, tolterodine, solifenacin, darifenacin, trospium, imidafenacin, and fesoterodine) clinically used to treat urinary dysfunction in patients with OAB. The basic pharmacological characteristics of these eight antimuscarinic agents include muscarinic receptor subtype selectivity, functional bladder selectivity, and muscarinic receptor binding in the bladder and other tissues...
April 27, 2018: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29699858/efficacy-and-tolerability-of-mirabegron-compared-with-antimuscarinic-monotherapy-or-combination-therapies-for-overactive-bladder-a-systematic-review-and-network-meta-analysis
#17
Con Kelleher, Zalmai Hakimi, Richard Zur, Emad Siddiqui, Khaled Maman, Samuel Aballéa, Jameel Nazir, Chris Chapple
BACKGROUND: Mirabegron is an established treatment alternative to antimuscarinic therapy for patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase III trials. OBJECTIVE: To assess efficacy and tolerability of mirabegron 50mg versus antimuscarinic monotherapies and combination therapies. DESIGN, SETTING, AND PARTICIPANTS: Systematic literature review and network meta-analysis of randomised controlled trials (2000-2017) assessing eligible treatments for OAB...
April 23, 2018: European Urology
https://www.readbyqxmd.com/read/29697209/efficacy-and-safety-of-mirabegron-a-%C3%AE-3-adrenoceptor-agonist-in-patients-with-detrusor-hyperactivity-and-impaired-contractility
#18
Cheng-Ling Lee, Hann-Chorng Kuo
OBJECTIVE: We examined the efficacy and safety of mirabegron in elderly patients with urodynamic detrusor hyperactivity with impaired contractility (DHIC). METHODS: Patients diagnosed with DHIC received daily dose of mirabegron (25mg). Subjective symptom scores, uroflowmetry data, and adverse events (AEs) were recorded for all patients at baseline and after 1, 3, and 6 months treatment. Comparisons were made for each patient individually and between patients with detrusor overactivity (DO)...
April 26, 2018: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/29692690/overactive-bladder-syndrome-evaluation-and-management
#19
REVIEW
Elad Leron, Adi Y Weintraub, Salvatore A Mastrolia, Polina Schwarzman
Overactive bladder (OAB) syndrome is a chronic medical condition which has a major influence on the quality of life in a significant amount of the population. OAB affects performance of daily activities and has an estimated prevalence of 16.5%. Many sufferers do not seek medical help. Moreover, many family physicians and even gynecologists are not familiar with this issue. Usually patients suffer from OAB in advanced age. Nocturia is reported as the most bothersome symptom in the elderly population. The aim of our review was to discuss all aspects of this challenging disorder and suggest tools for assessment and management strategies...
March 2018: Current Urology
https://www.readbyqxmd.com/read/29686801/cost-effectiveness-of-solifenacin-compared-with-oral-antimuscarinic-agents-for-the-treatment-of-patients-with-overactive-bladder-in-the-uk
#20
Zalmai Hakimi, Con Kelleher, Samuel Aballéa, Khaled Maman, Jameel Nazir, Colette Mankowski, Isaac Odeyemi
Objective: To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. Study design: In a Markov model, hypothetical patients received solifenacin 5 mg/day or a comparator antimuscarinic, after which they could switch to an alternative antimuscarinic. The model estimated incremental cost-effectiveness ratios (ICER), expressed as cost per quality-adjusted life year (QALY) over a 5-year period...
2018: Journal of Market Access & Health Policy
keyword
keyword
2889
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"